Characterization and performance of nucleic acid nanoparticles combined with protamine and gold

Abstract Macromolecular nucleic acids such as DNA vaccines, siRNA, and splice-site switching oligomers (SSO) have vast chemotherapeutic potential. Nanoparticulate biomaterials hold promise for DNA and RNA delivery when a means for binding is identified that retains structure–function and provides st...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials 2009-11, Vol.30 (32), p.6451-6459
Main Authors: DeLong, Robert K, Akhtar, Uzma, Sallee, Michael, Parker, Brooke, Barber, Stephanie, Zhang, Jie, Craig, Michael, Garrad, Richard, Hickey, Anthony J, Engstrom, Eric
Format: Article
Language:English
Subjects:
Advanced Basic Science
Dentistry
DNA nanoparticle
DNA vaccine
Drug Carriers - chemistry
Gold - chemistry
Materials Testing
Nanoparticles - therapeutic use
Nucleic Acids - administration & dosage
Nucleic Acids - chemistry
Nucleic Acids - genetics
Protamine
Protamines - chemistry
RNA nanoparticle
Splice-site switching oligonucleotide
Transfection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Macromolecular nucleic acids such as DNA vaccines, siRNA, and splice-site switching oligomers (SSO) have vast chemotherapeutic potential. Nanoparticulate biomaterials hold promise for DNA and RNA delivery when a means for binding is identified that retains structure–function and provides stabilization by the nanoparticles. In order to provide these benefits of binding, we combined DNA and RNA with protamine—demonstrating association to gold microparticles by electrophoretic, gel shot, fluorescence, and dynamic laser light spectroscopy (DLLS). A pivotal finding in these studies is that the Au–protamine–DNA conjugates greatly stabilize the DNA; and DNA structure and vaccine activity are maintained even after exposure to physical, chemical, and temperature-accelerated degradation. Specifically, protamine formed nanoparticles when complexed to RNA. These complexes could be detected by gel shift and were probed by high throughput absorbance difference spectroscopy (HTADS). Biological activity of these RNA nanoparticles (RNPs) was demonstrated also by a human tumor cell splice-site switching assay and by siRNA delivery against B-Raf—a key cancer target. Finally, RNA:protamine particles inhibited growth of cultured human tumor cells and bacteria. These data provide new insights into DNA and RNA nanoparticles and prospects for their delivery and chemotherapeutic activity.
ISSN:0142-9612
1878-5905
DOI:10.1016/j.biomaterials.2009.07.067